Table 3.

 

Branded drug (first launched biosimilar)	USA			Canada		UK
	# of patents on 3A list	# of patents asserted	# of months delay launch	# of patents asserted	# of months delay launch	# of patents asserted	# of months delay launch
Humira (Amgevita/Amgen)	61	10	75	0	6	4	19
Herceptin (Kanjinti/Amgen)	37	37	1	4	2	0	2
Rituxan (Truxima/Celltrion)	40	40	12	4	8	3	2
Avastin (Mvasi, Amgen)	29	27	22	1	16	1	No launch
Remicade (Remsima/Celltrion)	6	6	7	1	No launch	0	4
Enbrel (Erelzi/Sandoz)	5	5	151	2	4	0	0
Neulasta (Fulphila/Mylan)	2	2	1	1	15	2	No launch
Neupogen (Nivestim/Hospira)	8	2	3	1	1	0	1
Mean #	23.5	16.2	34	1.8	7.4	1.3	4.7